Loading...
Loading...
REVB| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 7,968.9M |
| Operating I/L | -7,968.9M |
| Other Income/Expense | -7,056.3M |
| Interest Income | 0.0M |
| Pretax | -15,025.2M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -15,025.2M |
Revelation Biosciences, Inc. is a clinical-stage biopharmaceutical company specializing in immune system therapeutics and diagnostics. The company's product pipeline includes REVTx-99b, a Phase Ib clinical trial candidate for chronic nasal congestion and allergic rhinitis; REVTx-200, a nonclinical stage intranasal therapy; REVTx-300, a potential therapy for chronic organ diseases; and REVDx-501, a rapid test kit for respiratory viral infections. These products are designed to address unmet medical needs and have the potential to generate revenue through commercialization and sales.
